Johnson & Johnson projects full-year 2026 sales between $100 billion and $101 billion, surpassing the consensus estimate of $98.5 billion. Adjusted earnings per share are forecast in a range of $11.43 to $11.63, reflecting management’s confidence in margin resilience. Morgan Stanley’s recent analysis assigns the company a potential 16.7% upside based on fundamentals, underscoring the strength of J&J’s diversified portfolio in pharmaceuticals, medical devices and consumer health.

In the fourth quarter, J&J delivered 9.1% revenue growth year-over-year, driven by robust demand in the Innovative Medicine segment, where launches such as Darzalex and Tremfya offset the loss of exclusivity for Stelara. MedTech likewise contributed double-digit growth, benefiting from strengthened U.S. surgical procedure volumes and pricing gains. U.S. consumer health sales remained resilient, bolstered by key wellness brands and demand for over-the-counter solutions.

Marking over 50 consecutive years of dividend increases, J&J continues to support its dividend program through strong free cash flow generation and disciplined capital allocation. The company’s market capitalization stands near $540 billion, with free cash flow conversion above 90%. Management has signaled a sustained commitment to returning at least 50% of adjusted earnings to shareholders via dividends and share repurchases, consistent with long-term plans for double-digit top-line growth and margin expansion.